Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this work was to investigate the clinical significance and the evolution of OLIG2 and CCND2 protein expression in GBM.
|
31568682 |
2020 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%).
|
31003026 |
2019 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that overexpression of YAP1 was sufficient to inhibit the OLIG2 proneural marker, suggesting its involvement in maintenance of the GBM phenotype.
|
30009411 |
2018 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed in GBM tissues the coexistence of functionally divergent micro-territories either enriched in more differentiated and non-mitotic cells or in mitotic undifferentiated OLIG2 positive cells while sharing similar genomic abnormalities.
|
28925399 |
2018 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that ARNT2 knockdown decreased the expression of SOX9, POU3F2 and OLIG2, transcription factors implicated in glioblastoma cell tumorigenicity, and repressed glioblastoma stem-like cell tumorigenic properties in vivo.
|
29149419 |
2018 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We validated this MMS on human glioblastoma tissue sections with the use of immunohistochemistry on preclassified (YKL-40 high or mesenchymal glioblastoma and OLIG2 high or proneural glioblastoma) tumor samples (<i>n</i> = 30).
|
28744448 |
2017 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the expression of Olig2, a protein responsible for the progression of glioblastoma was reduced by D609.
|
28802717 |
2017 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma.
|
26517684 |
2017 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The basic helix-loop-helix transcription factor OLIG2, which is universally expressed in gliomas, has emerged as an important player in GBM cell reprogramming, genotoxic resistance, and tumor phenotype plasticity.
|
28806136 |
2017 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Head of the Class: OLIG2 and Glioblastoma Phenotype.
|
27165737 |
2016 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Olig2 expressions were successfully detected in 12 (15.58%) of 77 SVZ type II GBs and 16 (21.3%) of 75 SVZ type III GBs, respectively.
|
27179219 |
2016 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This occurs because Omomyc interferes with proper MYC localization and itself associates with the genome, with a preference for sites occupied by MYC This is accompanied by selective repression of master transcription factors for glioblastoma stemlike cell identity such as OLIG2, POU3F2, SOX2, upregulation of effectors of tumour suppression and differentiation such as ID4, MIAT, PTEN, and modulation of the expression of microRNAs that target molecules implicated in glioblastoma growth and invasion such as EGFR and ZEB1.
|
27852622 |
2016 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.
|
25384509 |
2015 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Induction of the miR-302/367 cluster in extensively mutated U87MG glioblastoma cells drastically suppressed the expression of transformation related proteins, for example, the reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC, and the transcription factors POU3F2, SALL2 and OLIG2, required for the maintenance of glioblastoma stem-like tumor propagating cells.
|
25991553 |
2015 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identify a core set of neurodevelopmental TFs (POU3F2, SOX2, SALL2, and OLIG2) essential for GBM propagation.
|
24726434 |
2014 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, LGR5 expression may be functionally correlated with the neurogenic competence, and be regulated by OLIG2 in GSCs.
|
23793848 |
2013 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We provide evidence that sorafenib has a selective action on glioblastoma stem cells, causing enrichment of cultures in differentiated cells, downregulation of the expression of stemness markers required to maintain malignancy (nestin, Olig2 and Sox2) and reducing cell clonogenic ability in vitro and tumorigenic potential in vivo.
|
23324350 |
2013 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Olig-2 stained 22 (91.6%) of 24 oligodendrogliomas and all dysembryoplastic neuroepithelial tumors but also 24 (80%) of 30 glioblastoma multiforme and 8 (80%) of 10 pilocytic astrocytomas.
|
21835431 |
2012 |
Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High expression of proneural gene OLIG2 without EGFRvIII expression may be associated with a favorable clinical outcome; however, IDH1/2 gene status and the extent of LOH regions may indicate that this small subgroup of GBM is a distinct genetic subgroup from oligodendroglial tumors.
|
22736234 |
2012 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
With dual-labeling, glioblastoma had the highest percentage of OLIG2 expressing cells that were also Ki-67 positive (mean = 16.3%) whereas pilocytic astrocytoma WHO grade I and astrocytoma WHO grade II had the lowest (0.9 and 1%, respectively); most of the Ki-67 positive cells in the diffuse-type astrocytomas (WHO grade II-III) were also OLIG2 positive (92-94%).
|
21193945 |
2011 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further analyses confirmed same transcription directions for Olig2 and IL-13Ralpha2 in anaplastic astrocytomas as compared to glioblastomas.
|
17917751 |
2008 |
Glioblastoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Here, we investigated the effect of OLIG2 expression on the migration of the human glioblastoma cell line U12-1.
|
17951409 |
2007 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we investigated the effect of OLIG2 expression on the migration of the human glioblastoma cell line U12-1.
|
17951409 |
2007 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the function of OLIG2 in glial tumor cells, we have established a glioblastoma cell line, U12-1, in which the expression of OLIG2 is induced by the Tet-off system.
|
16554441 |
2006 |
Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Olig1 and Olig2 were expressed in 26/30 (87%) and 28/30 (93%) of oligodendroglial tumors respectively but in only 9% of glioblastomas (1/11).
|
15164981 |
2004 |